Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.

ABSTRACT: Context:In healthy individuals, glucose-dependent insulinotropic polypeptide (GIP) enhances insulin secretion and reduces bone resorption by up to 25% estimated by absolute placebo-corrected changes in carboxy-terminal type 1 collagen crosslinks (CTX) during GIP and glucose administration. In patients with type 2 diabetes (T2D), GIP's insulinotropic effect is impaired and effects on bone may be reduced. Objective:To investigate GIP's effect on bone biomarkers in patients with T2D. Design:Randomized, double-blinded, crossover study investigating 6 interventions. Patients:Twelve male patients with T2D. Interventions:A primed continuous 90-minute GIP infusion (2 pmol/kg/min) or matching placebo (saline) administered at 3 plasma glucose (PG) levels (i.e., paired days with "insulin-induced hypoglycemia" (PG lowered to 3 mmol/L), "fasting hyperglycemia" (mean PG ~8 mmol/L), or "aggravated hyperglycemia" (mean PG ~12 mmol/L). Main Outcome Measures:Bone biomarkers: CTX, procollagen type 1 N-terminal propeptide (P1NP) and PTH. Results:On days with insulin-induced hypoglycemia, CTX was suppressed by up to 40?±?15% during GIP administration compared with 12?±?11% during placebo infusion (P?

SUBMITTER: Christensen MB 

PROVIDER: S-EPMC7458112 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature